The most immediate effect of the deal is a much-needed infusion of funds for Repare, which went public in 2020 at a price of $20 a share. The company’s stock soared above $42 in early 2021, only to plummet as investors turned sour on biotech startups.
Repare ended the first quarter with $312 million in cash, cash equivalents and marketable securities. With the Roche deal in hand, company executives told investors the biotech’s cash runway will be extended into 2026.
